Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health IT Reg Bill Sparks Debate; AdvaMed Tries To Address “Technical Concerns”

This article was originally published in The Gray Sheet

Executive Summary

The PROTECT Act, introduced by Sens. Fischer, R-Neb., and King, I-Maine, earlier this month to restrict FDA oversight of software tools has already triggered some high-profile discussion, with a USA Today op-ed from sponsors and an opposition letter from consumer groups. AdvaMed, meanwhile, is playing more of a behind-the-scene role.

You may also be interested in...

Health IT Deregulation Bill Introduced In Senate, With Powerful Industry Backers

The PROTECT Act, which attempts to respond to some criticisms of the House SOFTWARE Act, aims to restrict FDA’s oversight of health information technology. It is backed by IBM and Verizon, among others.

Representatives Grill Shuren, Advance SOFTWARE Act

Tennessee Republican Rep. Marsha Blackburn’s SOFTWARE Act advanced to the Health Subcommittee of the House Energy & Commerce Committee Nov. 19, where representatives grilled CDRH Director Jeffrey Shuren on health information technology regulation.

Health IT Workgroup’s Final Regulatory Recommendations Approved

The final recommendations from the FDASIA workgroup urge the government to focus regulatory attention on the highest risk products, while minimizing requirements for the large swath of health IT offerings that are lower risk. The recommendations, which largely align with a prior draft version, will inform a health IT regulatory framework proposal due to Congress in January.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts